Abstract: A medico-legal template process, created by the Medical—Nursing community, that audio-visually demonstrates actual injury and trauma of a patient physically, functionally, mentally, emotionally and psychologically, and it's impact on altering that patient's pre-morbid/baseline activities of daily living, and relationships, both short and long term. The audio-visual record is a patient focused, neutral, medical and nursing assessment and analysis application for the discovery, mediation and litigation components of personal injury and medical malpractice law, and other applicable fields of study. This material is unique and original in that it applies the Nursing Process to the Clinical Forensic Video, it is created by the Medical-Nursing community for the Legal community, and it creates a neutral position within Plaintiff and Defense litigation.

Abstract: A tailorable polyimide prepolymer blend comprising an end group component, a dianhydride component, and a diamine component. The dianhydride component includes at least 3,4,3?,4?-benzophenonetetracarboxylic dianhydride (BTDA), derivatives thereof, or combinations thereof, and 3,4,3?,4?-biphenyltetracarboxylic dianhydride (BPDA), derivatives thereof, or combinations thereof. The diamine component includes at least 1,3-phenylenediamine (mPDA), derivatives thereof, or combinations thereof; 1,4-phenylenediamine (pPDA), derivatives thereof, or combinations thereof; bis amino phenoxy benzene (APB), derivatives thereof, and combinations thereof; and optionally, 4,4?-(1,3-phenylene-bis(1-methylethylidene)bisaniline (Bis-M), derivatives thereof, and combinations thereof. A cured polyimide matrix has a glass transition temperature of at least about 450° F. (232° C.).

Abstract: A tailorable polyimide prepolymer blend comprising an end group component, a dianhydride component, and a diamine component. The dianhydride component includes at least 3,4,3?,4?-benzophenonetetracarboxylic dianhydride (BTDA), derivatives thereof, or combinations thereof, and 3,4,3?,4?-biphenyltetracarboxylic dianhydride (BPDA), derivatives thereof, or combinations thereof. The diamine component includes at least 1,3-phenylenediamine (mPDA), derivatives thereof, or combinations thereof, 1,4-phenylenediamine (pPDA), derivatives thereof, or combinations thereof, bis amino phenoxy benzene (APB), derivatives thereof, and combinations thereof, and optionally, 4,4?-(1,3-phenylene-bis(1-methylethylidene) bisaniline (Bis-M), derivatives thereof, and combinations thereof. A cured polyimide matrix has a glass transition temperature of at least about 450° F. (232° C.).

Abstract: A tailorable polyimide prepolymer blend including a diamine component including 1,3-phenylenediamine (mPDA), Bisaniline M, and 1,4-phenylenediamine (pPDA), a dianhydride component including 3,4,3?,4?-benzophenonetetracarboxylic dianhydride (BTDA) and 3,4,3?,4?-biphenyltetracarboxylic dianhydride (BPDA), and an end group component. The components may be provided as a monomeric mixture. The prepolymer blend, prior to cure, may provide at least one predetermined prepolymer blend property; and the cured prepolymer blend may provide a crosslinked polyimide matrix having at least one predetermined crosslinked matrix property. Articles formed from the tailorable polyimide prepolymer blend may include powders, neat resins, coating materials, films, adhesives, fibers, composites, laminates, prepregs and parts.

Abstract: A method of performing a medical procedure is provided. The medical procedure includes stimulation of a patient's heart while stimulating a nerve of the patient in order to modulate the patient's inflammatory process. More particularly, the medical procedure includes pacing the ventricles of the patient's heart while stimulating the vagal nerve of the patient. Systems and devices for performing the medical procedure are also provided.

Abstract: Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.

Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NF?B family of transcription factors.

Abstract: Disclosed herein are methods and sequences used to treat pain. Specifically, the methods and sequences include locally administering nucleic acid molecules that suppress the expression of amino acid sequences that encode for pro-inflammatory cytokines and their receptors to treat acute or neuropathic pain associated with sciatica.

Abstract: Methods and devices to enhance anti-inflammatory effects in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, pain and brain injury are described. Anti-inflammatory enhancing agents that target IL-10 production and signal transduction pathways are discussed. Devices described include therapy delivery devices comprising a reservoir capable of housing an anti-inflammatory enhancing agent and a catheter operably coupled to the device and adapted to deliver the agent to a target site within a subject.

Abstract: Methods and devices to attenuate tumor necrosis factor (TNF) and other pro-inflammatory mediators in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, and brain injury are described. More particularly, TNF blocking agents that target TNF-receptor interactions and the effects of downstream secreted cytokines associated with an inflammatory cascade are described. Such TNF blocking agents are administered directly to the brain by, for example, intraparenchymal administration, intracerebroventricular administration, or administration into a cerebral artery. Devices described include therapy delivery devices comprising a reservoir capable of housing a TNF blocking agent and a catheter operably coupled to the device and adapted to deliver the TNF blocking agent to a target site within a subject.

Abstract: Devices and methods for treating diseases associated with loss of neuronal function by cell replacement therapy are described. The methods are designed to promote proliferation, differentiation, migration, or integration of exogenous stem cells transplanted into the central nervous system (CNS). A therapy, such as an electrical signal or a stem cell enhancing agent, or a combination of therapies, is applied to a CNS region having damaged neuronal tissues, into which region exogenous stem cells are transplanted. A therapy may also be applied to a second region of the CNS to which neurons from the damaged CNS region are expected to project. The exogenous stem cells may be transfected with an electrically responsive genetic construct comprising an electrically responsive promoter and a target gene.

Abstract: Devices and methods for treating diseases associated with loss of neuronal function are described. The methods are designed to promote proliferation, differentiation, migration, or integration of endogenous progenitor stem cells of the central nervous system (CNS). A therapy, such as an electrical signal or a stem cell enhancing agent, or a combination of therapies, is applied to a CNS region containing endogenous stem cells or a CNS region where the endogenous stem cells are predicted to migrate and eventually reside, or a combination thereof.

Abstract: Methods and devices to attenuate tumor necrosis factor (TNF) and other pro-inflammatory mediators in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, pain and brain injury are described. More particularly, TNF blocking agents that target intracellular signals and downstream effects associated with the production and secretion of TNF are described. Devices described include therapy delivery devices comprising a reservoir capable of housing a TNF blocking agent and a catheter operably coupled to the device and adapted to deliver the TNF blocking agent to a target site within a subject.

Abstract: Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.

Abstract: Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.